收费全文 | 25830篇 |
免费 | 1351篇 |
国内免费 | 66篇 |
耳鼻咽喉 | 368篇 |
儿科学 | 2032篇 |
妇产科学 | 612篇 |
基础医学 | 2961篇 |
口腔科学 | 478篇 |
临床医学 | 1412篇 |
内科学 | 4801篇 |
皮肤病学 | 986篇 |
神经病学 | 1135篇 |
特种医学 | 956篇 |
外科学 | 3878篇 |
综合类 | 916篇 |
一般理论 | 10篇 |
预防医学 | 1269篇 |
眼科学 | 1318篇 |
药学 | 2114篇 |
中国医学 | 140篇 |
肿瘤学 | 1861篇 |
2023年 | 149篇 |
2022年 | 380篇 |
2021年 | 742篇 |
2020年 | 412篇 |
2019年 | 475篇 |
2018年 | 691篇 |
2017年 | 456篇 |
2016年 | 668篇 |
2015年 | 589篇 |
2014年 | 920篇 |
2013年 | 1082篇 |
2012年 | 1534篇 |
2011年 | 1628篇 |
2010年 | 883篇 |
2009年 | 710篇 |
2008年 | 1231篇 |
2007年 | 1306篇 |
2006年 | 1123篇 |
2005年 | 1061篇 |
2004年 | 956篇 |
2003年 | 886篇 |
2002年 | 798篇 |
2001年 | 723篇 |
2000年 | 683篇 |
1999年 | 596篇 |
1998年 | 244篇 |
1997年 | 179篇 |
1996年 | 144篇 |
1995年 | 136篇 |
1994年 | 114篇 |
1993年 | 130篇 |
1992年 | 356篇 |
1991年 | 390篇 |
1990年 | 342篇 |
1989年 | 358篇 |
1988年 | 308篇 |
1987年 | 277篇 |
1986年 | 268篇 |
1985年 | 279篇 |
1984年 | 219篇 |
1983年 | 181篇 |
1979年 | 241篇 |
1978年 | 158篇 |
1977年 | 148篇 |
1976年 | 135篇 |
1975年 | 163篇 |
1974年 | 154篇 |
1973年 | 176篇 |
1972年 | 138篇 |
1971年 | 122篇 |
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)